Investment Thesis
Cigna demonstrates solid revenue growth of 11.2% YoY in an essential healthcare sector, but fundamental quality is questionable with net income declining despite top-line expansion, razor-thin profitability (2.4% net margin), and concerning liquidity ratios (0.82x current ratio). The company generates minimal free cash flow ($81M on $68.5B revenue) and delivers poor returns on capital (ROE 3.9%, ROA 1.1%), suggesting operational challenges and inefficient capital deployment that warrant caution.
Strengths
- Strong revenue growth of 11.2% YoY demonstrating market demand and scale expansion
- Manageable leverage with 0.70x debt-to-equity ratio and solid 6.6x interest coverage capacity
- Significant asset base of $153.3B providing operational scale and market position in essential healthcare services
Risks
- Net income declined 5.3% YoY despite 11.2% revenue growth, indicating margin compression or rising operational costs that offset top-line gains
- Liquidity concerns with current ratio of 0.82x and quick ratio of 0.71x (both below 1.0 threshold) raise working capital management questions
- Critically weak free cash flow generation of only $81M (0.1% FCF margin) with operating cash flow nearly equal to capex, limiting financial flexibility and shareholder returns
Key Metrics to Watch
- Net margin trend - must stabilize above current 2.4% to validate operational improvements
- Operating cash flow to net income conversion - monitor if FCF margin can exceed 1-2% sustainably
- Current and quick ratio trajectory - liquidity ratios need improvement toward industry benchmarks above 1.0x
Financial Metrics
Revenue
68.5B
Net Income
1.7B
EPS (Diluted)
$6.26
Free Cash Flow
81.0M
Total Assets
153.3B
Cash
7.0B
Profitability Ratios
Gross Margin
N/A
Operating Margin
3.4%
Net Margin
2.4%
ROE
3.9%
ROA
1.1%
FCF Margin
0.1%
Balance Sheet & Liquidity
Current Ratio
0.82x
Quick Ratio
0.71x
Debt/Equity
0.70x
Debt/Assets
72.3%
Interest Coverage
6.61x
Long-term Debt
29.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T17:15:05.780043 |
Data as of: 2026-03-31 |
Powered by Claude AI